Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

OBJECTIVE: To investigate the regulation of expression of the angiogenic cytokine vascular endothelial growth factor (VEGF) in rheumatoid arthritis (RA), in order to determine whether new blood vessel formation could be a potential therapeutic target in RA. METHODS: Dissociated RA synovial membrane cells were cultured in the presence of cytokine inhibitors, or under hypoxic conditions. Serum VEGF levels were serially measured in RA patients enrolled in clinical trials of anti-tumor necrosis factor alpha (anti-TNFalpha) monoclonal antibody treatment. RESULTS: Combined neutralization of TNFalpha and interleukin-1 (IL-1) in RA synovial membrane cultures reduced VEGF release by 45% (P < 0.05 versus control), although blockade of either TNFalpha or IL-1 activities alone resulted in only small inhibitory effects. In addition, release of VEGF from RA synovial membrane cells was selectively up-regulated by hypoxia. Serum VEGF levels were significantly elevated in RA patients relative to control subjects, and correlated with disease activity. Treatment of RA patients with anti-TNFalpha significantly decreased serum VEGF, and this effect was enhanced by cotreatment with methotrexate. CONCLUSION: Inhibition of TNFalpha and IL-1 activity in vivo could reduce the drive to new blood vessel formation, and hence pannus mass, adding to other therapeutic effects of anti-TNFalpha therapy in RA.

Original publication

DOI

10.1002/1529-0131(199807)41:7<1258::aid-art17>3.0.co;2-1

Type

Journal article

Journal

Arthritis and rheumatism

Publication Date

07/1998

Volume

41

Pages

1258 - 1265

Addresses

Kennedy Institute of Rheumatology, London, UK.

Keywords

Synovial Membrane, Cells, Cultured, Humans, Arthritis, Rheumatoid, Methotrexate, Vascular Endothelial Growth Factors, Vascular Endothelial Growth Factor A, Endothelial Growth Factors, Sialoglycoproteins, Tumor Necrosis Factor-alpha, Receptors, Interleukin-1, Interleukin-1, Antibodies, Monoclonal, Lymphokines, Enzyme-Linked Immunosorbent Assay, Double-Blind Method, Cell Hypoxia, Gene Expression Regulation, Dose-Response Relationship, Drug, Interleukin 1 Receptor Antagonist Protein